Why the study?
Does statin therapy provide a better risk-to-benefit profile than aspirin for the primary prevention of cardiovascular disease?
Does statin therapy provide a better risk-to-benefit profile than aspirin for the primary prevention of cardiovascular disease?
Statins offer a more favorable risk-to-benefit profile than aspirin for the primary prevention of cardiovascular disease due to greater absolute risk reduction and lower severe adverse event rates.
Answers are grounded in this paper and cite their sources.
Statins may be preferred over aspirin for primary prevention; leaves open need for direct comparative trials.
For the primary prevention of cardiovascular (CV) disease, aspirin reduces the risk for major vascular events by approximately 15% to 20% with an absolute reduction of approximately 0.1%. Major bleeding occurs at an excess of approximately 2 cases per 1000 patient-years with aspirin therapy. For primary prevention, statin therapy has been shown to reduce the risk of CV events by approximately 30% to 40% with an absolute reduction of 1% to 2%. Rhabdomyolysis is rare, with an incidence of 3.4 cases per 100 000 patient-years. Compared with aspirin, statins have a more favorable risk-to-benefit profile for primary prevention.
No takes yet. Share an insight, caveat, or question.
Dietrich et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: